Aurinia Pharmaceuticals Inc (AUPH.xnas) is a late-stage clinical biopharmaceutical company headquartered in Victoria, British Columbia, Canada. Aurinia is developing and commercialising therapies to treat targeted patient populations with serious diseases with high unmet medical needs. The company employs 294 people, has a US commercial hub in Rockville and Maryland, and extends to other global areas. The Aurinia Pharmaceuticals Inc stock is listed on the NASDAQ and had a market capitalisation of $2.41B (USD) as of January 2022. In December 2020, Aurinia Pharmaceuticals and Otsuka Pharmaceuticals entered a collaboration and licensing agreement to develop and commercial oral voclosporin as a treatment for Lupus nephritis (LN) in the European Union, Japan, United Kingdom, and Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein, and Ukraine. Aurinia Pharmaceuticals announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS (voclosporin) for the treatment of adults with active lupus nephritis. The LUPKYNIS is the first and only approved medicine from FDA with 3 years of pivotal trial results, including long-term safety data, within LN.
Aurinia Pharmaceuticals Inc (AUPH)
Get Aurinia Pharmaceuticals Inc (AUPH) share price news and insights for better investment decisions. Stay updated with FP Markets South Africa.